Request Your Free White Paper Now:

"How cell and gene therapies are forcing sponsors to rethink safety and efficacy monitoring"

Cell and gene therapies are transforming healthcare. Sponsors need to realize the potential now, forcing a rethink of monitoring to manage complexity.

Cell and gene therapies are transforming cancer treatment. Patients who would only live a few months on older treatments now have options that can significantly extend their lives. Sponsors are under pressure to realize the vast potential as quickly as possible, forcing them to rethink safety and efficacy monitoring to cope with the complexity of such therapies and their logistics.

In this whitepaper, we look at how the industry is rising to the challenge, focusing on how cell and gene therapies are radically improving health outcomes and the technologies and techniques that are facilitating their development. The paper covers:

• How cell and gene therapies are upending drug development
• The role of assay development, logistics and flow cytometry
• What is needed to effectively support cell and gene therapy trials
• Real-world examples of safety and efficacy monitoring

Offered Free by: Cerba Research
See All Resources from: Cerba Research